112575-13-0

Basic information

• Product Name: 6-Bromo-2-N,N-dimethylaminopyridine
• Synonyms: 6-Bromo-2-N,N-dimethylaminopyridine;6-bromo-N,N-dimethylpyridin-2-amine;(6-BroMo-pyridin-2-yl)-diMethyl-aMine;2-Bromo-6-(dimethylamino)pyridine;6-Bromo-2-(dimethylamino)pyridine
• CAS NO: 112575-13-0
• Molecular Formula: C₇H₉BrN₂
• Molecular Weight: 201.066
• Product Categories: alkyl bromide
• Mol File: 112575-13-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 56-57 °C(Solv: cyclohexane (110-82-7))
• Boiling Point: 282.0±20.0 °C(Predicted)
• Appearance: /
• Density: 1.469±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 3.51±0.10(Predicted)
• CAS DataBase Reference: 6-Bromo-2-N,N-dimethylaminopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromo-2-N,N-dimethylaminopyridine(112575-13-0)
• EPA Substance Registry System: 6-Bromo-2-N,N-dimethylaminopyridine(112575-13-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 112575-13-0(Hazardous Substances Data)

Usage

General Description

6-Bromo-2-N,N-dimethylaminopyridine is a chemical compound with the molecular formula C8H10BrN3. It is a pyridine derivative that is commonly used as a reagent in organic synthesis and pharmaceutical research. 6-Bromo-2-N,N-dimethylaminopyridine is a versatile and efficient catalyst for a variety of chemical reactions, including Suzuki-Miyaura cross-coupling reactions and Buchwald-Hartwig amination reactions. 6-Bromo-2-N,N-dimethylaminopyridine is known for its high reactivity and selectivity, making it a valuable tool for the synthesis of complex organic molecules. Additionally, the unique combination of bromine and dimethylamino functional groups in this compound provides it with distinct properties that set it apart from other pyridine derivatives.

Upstream product

• 19798-81-3 2-Amino-6-bromopyridine 
• 50-00-0 formaldehyd 
• 74-88-4 methyl iodide 
• 144100-07-2 2-bromo-6-fluoropyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 626-05-1 2,6-Dibromopyridine 
• 74-89-5 methylamine 
• 124-40-3 dimethyl amine 

Downstream Products

• 1356336-25-8 N,N-dimethyl-6-(4-(trifluoromethyl)phenyl)pyridin-2-amine 
• 1356336-24-7 4-(6-(dimethylamino)pyridin-2-yl)benzonitrile 
• 1220595-99-2 benzyl 2-(6-(dimethylamino)pyridin-2-yl)ethylcarbamate 
• 1208348-08-6 6-(2-amino-5-methylphenyl)-N,N-dimethylpyridin-2-amine 
• 1208348-07-5 6-(2-aminophenyl)-N,N-dimethylpyridin-2-amine 

Relevant articles and documents

Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors

Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) regulates the proliferation and differentiation of neuronal progenitor cells during brain development. Consequently, DYRK1A has attracted interest as a target for the treatment of neurodegenerative diseases, including Alzheimer's disease (AD) and Down's syndrome. Recently, the inhibition of DYRK1A has been investigated as a potential treatment for diabetes, while DYRK1A's role as a mediator in the cell cycle has garnered interest in oncologic indications. Structure-activity relationship (SAR) analysis in combination with high-resolution X-ray crystallography leads to a series of pyrazolo[1,5-b]pyridazine inhibitors with excellent ligand efficiencies, good physicochemical properties, and a high degree of selectivity over the kinome. Compound 11 exhibited good permeability and cellular activity without P-glycoprotein liability, extending the utility of 11 in an in vivo setting. These pyrazolo[1,5-b]pyridazines are a viable lead series in the discovery of new therapies for the treatment of diseases linked to DYRK1A function.

BENZOSULFONYL COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.